When a country has no treatment available (and the next trial won't deliver results for at least 6 more months, remember CD10 was completed last summer) it doesn't need to "focus" anywhere. It just validates whatever comes through with statistically significant results. This in turn could provide more treatment opportunities to physicians, including borderline moderate/severe patiens. Zero country did that with Leronlimab after CD10. Let's face it, CD10 was a complete failure, worldwide.
Market Data 
Markets 
AI
